This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

The Quick Take
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to Inc.com.



